Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease (INHERIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04109300|
Recruitment Status : Not yet recruiting
First Posted : September 30, 2019
Last Update Posted : September 30, 2019
Inflammatory bowel disease (IBD) is a common disease in Canada, leading to significant morbidity as a result of remitting and relapsing intestinal inflammation. Currently, tumor necrosis factor (TNF) antagonists such as infliximab, make up 30% of the biologic agents available to individuals with IBD. There is a high risk of losing response or having a hypersensitivity reaction to infliximab, necessitating treatment discontinuation. This is due, in part, to the formation of anti-drug antibodies (ADAs). ADA formation can result in loss of response to therapy which may eliminate an intestine-saving therapy and increases their risk of progressing to surgical resection. There are few tools clinicians can implement to minimize the risk of ADA formation. The current approach is to add a second drug (known as combination therapy), specifically an immunomodulator (methotrexate or azathioprine), exposing the patient to additional medication-related risks, intensive monitoring with bi-weekly blood work and potential side effects including infection and malignancy.
Preliminary data from our group as well as others suggests that individuals who carry a variant in the class 2 human leukocyte antigen (HLA) gene (HLADQA1*05A>G, rs2097432) are more likely to form ADAs to infliximab. Pre-emptive screening for this variant may allow clinicians to more selectively use combination therapy, recommending it only in IBD patients at high risk of developing ADAs to infliximab. Additionally, this may result in fewer drug-associated adverse events.
With this project, we aim to explore the value of prospective HLADQA1*05 screening (pharmacogenomic screening) in IBD patients being considered for treatment with infliximab and using the result to guide the application of combination therapy compared to IBD patients treated with infliximab (with or without a second agent) as per current practice. We will assess the incidence of infliximab ADA formation, as well as the incidence of infliximab loss of response, treatment discontinuation, and adverse drug events. Additionally, we will assess the time to each of these events.
|Condition or disease||Intervention/treatment||Phase|
|Inflammatory Bowel Diseases Ulcerative Colitis Crohn Disease||Genetic: HLADQA1*05A>G screening Other: Standard of Care||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||162 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Participants will be randomized 1:1 to prospective HLADQA1*05A>G screening and targeted administration of combination therapy or standard of care (administration of combination therapy is at the discretion of the treating physician) and followed up to one year or until infliximab discontinuation. HLADQA1*05A>G genotyping will be performed in the standard of care group; however, investigators will remain blinded to this outcome until study completion.|
|Masking:||Double (Participant, Outcomes Assessor)|
|Masking Description:||This will be a single-blinded study. The treating gastroenterologist will be unblinded to the participant's allocation, while the assessor seeing the patient at the initial visit (PM Clinic) and at the subsequent follow up visits (week 14, week 26, week 52) will be blinded to the intervention (preemptive screening versus standard do care).|
|Official Title:||Pharmacogenomic Strategies in Inflammatory Bowel Disease: Evaluating the Role of Pre-emptive HLADQA1 Genotyping for the Application of Targeted Infliximab-based Combination Therapy (INHERIT)|
|Estimated Study Start Date :||September 1, 2020|
|Estimated Primary Completion Date :||September 1, 2023|
|Estimated Study Completion Date :||September 1, 2023|
Experimental: preemptive screening
prospective HLADQA1*05A>G screening and targeted administration of combination therapy of infliximab with one of either methotrexate or azathioprine.
Genetic: HLADQA1*05A>G screening
DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
Active Comparator: standard of care
administration of combination therapy with infliximab and one of methotrexate or azathioprine is at the discretion of the treating physician. HLADQA1*05A>G genotyping will be performed retrospectively.
Other: Standard of Care
The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
- incidence of infliximab anti-drug antibodies [ Time Frame: 1 year ]Evaluate the impact of pharmacogenomic screening and the administration of targeted-combination infliximab therapy to high risk (variant-carrying) individuals compared to an unscreened IBD population receiving standard of care (where combination therapy is administered at the discretion of the physician) on the incidence of infliximab ADA formation. Infliximab ADA formation is defined as any detectable amount of ADA in the absence of detectable serum infliximab (measured by enzyme-linked immunosorbent assay, ELISA).
- incidence of infliximab loss of response [ Time Frame: 1 year ]defined as a relapse in clinical symptoms after week 14 of infliximab dosing, with an increase in the Harvey Bradshaw index (HBI) ≥ 3 points or the partial Mayo score ≥ 3 points, following a response to infliximab induction therapy where a 3-point reduction was seen in the HBI or partial Mayo score
- incidence of infliximab discontinuation [ Time Frame: 1 year ]when stopped by treating physician
- incidence of infliximab-related adverse drug events [ Time Frame: 1 year ]defined as any injury presumed secondary to infliximab exposure as deemed by the treating gastroenterologist. This is including but not limited to: infection, immediate infusion reaction, delayed infusion reaction, psoriaform rash
- incidence of immunomodulator-related adverse drug events [ Time Frame: 1 year ]defined as any injury presumed secondary to azathioprine or methotrexate exposure as decided by the treating gastroenterologist. This is including, but not limited to: infection, nausea and dyspepsia, myelotoxicity, hepatoxicity, pancreatitis
- incidence of combination therapy (infliximab and one of methotrexate or azathioprine) -related adverse drug events [ Time Frame: 1 year ]defined in outcome 4 and 5
- time to infliximab anti-drug antibody formation [ Time Frame: 1 year ]measured from the time of treatment initiation to the time of antibody formation
- time to infliximab loss of response [ Time Frame: 1 year ]measured from the time of treatment initiation to the time of infliximab loss of response defined as a relapse in clinical symptoms after week 14 of infliximab dosing, with an increase in the Harvey Bradshaw index (HBI) ≥ 3 points or the partial Mayo score ≥ 3 points, following a response to infliximab induction therapy where a 3-point reduction was seen in the HBI or partial Mayo score.
- time to infliximab discontinuation [ Time Frame: 1 year ]measured from the time of treatment initiation to the time of cessation as decided by the treating physician.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04109300
|Contact: Aze A Wilson, MD, PhDfirstname.lastname@example.org|
|Contact: Reena Khanna, MD||519-685-8500 ext email@example.com|
|London, Ontario, Canada, N6A 3K7|
|Contact: Aze A Wilson 5196633832 firstname.lastname@example.org|
|Principal Investigator: Aze A Wilson, MD, PhD|
|Sub-Investigator: Reena Khanna, MD|
|Sub-Investigator: Melanie D Wilson, MD|
|Sub-Investigator: Vipul Jairath, MD, PhD|
|Sub-Investigator: Richard B Kim, MD|
|Principal Investigator:||Aze A Wilson, MD, PhD||Western University|